Third Annual Pediatric Cancer Symposium
The Third Annual Pediatric Cancer Symposium is designed to provide the latest information on Emerging Cancer Therapies: Targeting the Tumor Microenvironment and will benefit health care providers and researchers who work with childhood cancers and researchers.
It will allow pediatric cancer providers and researchers an opportunity to network, collaborate and advance treatment and research in discovering new cancer therapies.
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Medical College of Wisconsin designates this activity for up to 5.0 hours of participation for continuing education for allied health professionals.
Physicians, Allied Health Care Professionals
Describe the threshold effect of localized IL-12 overexpression in driving anti-cancer immunotherapy.
Delineate the mechanisms of localized IL-12 effects in antigen-independent immunotherapy.
Outline a novel clinical gene therapy trial that has been approved for this approach in treating AML and is actively recruiting patients.
Define the different mechanisms that contribute to tumor heterogeneity
Understand how the microenvironment interacts with tumor cells to contribute to cell plasticity
Understand how cell plasticity functions as a major mediator of Ewing sarcoma metastasis
Discuss the potential therapeutic implications of this for cancer therapy
Understand basic principles of B cell selection and cellular origins of childhood ALL
Compare the paradigm of targeted therapy in cancer (e.g. tyrosine kinase inhibitors) with targeted hyperactivation of signaling (tolerance checkpoints).
Discuss how pharmacological hyperactivation of oncogenic signaling triggers deletional checkpoints for elimination of autoreactive B cells
Review the current clinical and biological biomarkers that are utilized to risk classify neuroblastoma patients and stratify treatment.
Describe the germline genomic variants that contribute to the phenotype of neuroblastoma tumors 3. To discuss the observed racial and ethnic disparities in survival in neuroblastoma and the factors that contribute to these disparities.
Program Director: Michael Kelly, MD, MPH
Thomas Gajewski, MD, PhD
Raghu Kalluri, MD, PhD
Elizabeth Lawlor, MD, PhD
Jeffrey Medin, PhD
Markus Muschen, MD, PhD
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following person(s)
Susan Cohn, MD
EDWARDS LIFESCIENCES CORP COM
Susan Cohn and husband, James Cohn
Jeffrey Medin, PhD
Ownership instrest and consulting
- 5.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 5.00 Hours of ParticipationHours of Participation credit.